OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 61. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
“Fighting the pandemic!” Western Australian pharmacists’ perspectives on COVID-19 vaccines: A qualitative study	820
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	216
Characterization of gH/gL/pUL128-131 pentameric complex, gH/gL/gO trimeric complex, gB and gM/gN glycoproteins in a human cytomegalovirus using automated capillary western blots	194
Knowledge, attitudes, and practices regarding seasonal influenza vaccination during pregnancy in Costa Rica: A mixed-methods study	192
Increasing Ebola transmission behaviors 6 months post-vaccination: Comparing vaccinated and unvaccinated populations near 2018 Mbandaka Ebola outbreak in the Democratic Republic of Congo	188
Editorial Board/Aims and Scope	188
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	169
Editorial Board/Aims and Scope	146
Managing multiplicity in clinical vaccine studies – A case study using a gatekeeping testing strategy	136
Epidemiological characteristics and serotype distribution of culture-confirmed pediatric pneumococcal pneumonia before and after PCV 10 introduction, a multicenter study in Bogota, Colombia, 2008–2019	134
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration	129
Influenza vaccination in children with pulmonary disease during the COVID-19 pandemic	126
A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine	125
Cost of illness due to pertussis in adults ≥50 years of age in the United Kingdom	121
Mass vaccination campaign during the 2016 influenza outbreak in Panama: Challenges and implications for COVID-19 vaccination efforts	112
Editorial Board/Aims and Scope	106
Prevalence of indications for adult hepatitis A vaccination among hepatitis A outbreak-associated cases, Three US States, 2016–2019	105
Retesting the hypothesis that early Diphtheria-Tetanus-Pertussis vaccination increases female mortality: An observational study within a randomised trial	95
The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs	95
Tackling the burden of mumps in the military: A report of the Defense Health Board	93
Determinants of immunization in polio super high-risk union councils of Pakistan	93
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	92
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study	88
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	87
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	87

Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	86
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	85
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	85
Expected endpoints from future chikungunya vaccine trial sites informed by serological data and modeling	82
Collateral damage from debunking mRNA vaccine misinformation	81
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	79
World Health Organization Expert Working Group: Recommendations for assessing morbidity associated with enteric pathogens	78
Safety surveillance of varicella vaccine using tree-temporal scan analysis	78
Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study	77
BBIBP-CorV vaccine effectiveness against COVID-19 in patients aged 60 years and older during the Delta-dominant period in the Federation of Bosnia and Herzegovina, a test-negative case-control study	77
Characteristics of reported mumps cases in the United States: 2018–2023	75
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	75
“Every interaction you have …should be an opportunity to discuss and offer influenza vaccination”. Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families li	74
Knowledge, attitudes, and practices of healthcare providers regarding vaccinating children with cancer in Latin America and the Caribbean	74
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	71
Editorial Board/Aims and Scope	71
BCG for the prevention and treatment of allergic asthma	70
Editorial Board/Aims and Scope	70
Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?	70
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants	70
Have vaccine hesitancy models oversimplified a complex problem to our detriment? The Adapted Royal Society of Canada vaccine uptake framework	68
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	68
Corrigendum to ‘Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice’ [Vaccine 39 (2021) 6213–6220]	68
The U.S. COVID-19 vaccination program: A look back and future directions	67
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	66
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Medigen COVID-19 protein vaccine	66
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	66
Differences in school factors associated with adolescent HPV vaccination initiation and completion coverage in three Australian states	66
Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods	65
COVID-19 and seasonal influenza: The potential 2021–22 “Twindemic”	64
Impact analysis of rotavirus vaccination in various geographic regions in Western Europe	64
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	63
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	63
Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate	62
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season	62
Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis	61
Effectiveness of the varicella vaccine in the real world, a matched case-control study	61